Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

Holst JJ: Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002, 18: 430-441. 10.1002/dmrr.328.

Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1) – a trial of treatment in noninsulin-dependent diabetes mellitus. European J Clin Invest. 1997, 27: 533-536. 10.1046/j.1365-2362.1997.1490691.x.

Zander M, Madsbad S, Lysgaard J, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glucose control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002, 359: 824-830. 10.1016/S0140-6736(02)07952-7.

Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992, 326: 1316-1322.

Dupré J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ: Glucagon-like peptide 1 reduces post-prandial glucose excursions in IDDM. Diabetes. 1995, 44: 626-630.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care. 1996, 19: 580-586.

Dupré J, Behme MT, Hramiak IM, McDonald TJ: Subcutaneous glucagon-like peptide-1 combined with insulin normalizes postprandial glycemia in IDDM. Diabetes Care. 1997, 20: 381-384.

Dupré J, Jenner M, Mahon JL, Purdon C, Rodger NW, Stiller CR: Endocrine-metabolic function in remission-phase insulin-dependent diabetes mellitus (IDDM) during administration of cyclosporin. Diabetes. 1991, 40: 598-604.

Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk FW, Holst JJ, Rizza RA: Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes. Diabetes. 2001, 50: 565-572.

Kraegen EW, Chisholm DJ, McNamara ME: Timing of insulin delivery with meals. Horm Metab Res. 1981, 13: 365-367.

Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of Dipeptidyl Peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002, 25: 869-875.

Dupré J, Behme MT, McDonald TJ: Exendin-4 reduces glucose excursions after meals in insulin-treated diabetes. Abstract. Diabetes. 2002, 51 (Suppl 2): A84-

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O: Bedtime administration of NN2211 a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002, 51: 424-429.